A Multicenter, Randomized, Open Label, Clinical Trial to Evaluate Three Doses of Tipranavir Boosted With Ritonavir (500 mg/200 mg qd, 250 mg/100 mg Bid and 500 mg/100 mg Bid) by Assessing the Steady-State Pharmacokinetics and Short-Term Efficacy and Safety in HIV-1 Positive Treatment naive Patients.

Trial Profile

A Multicenter, Randomized, Open Label, Clinical Trial to Evaluate Three Doses of Tipranavir Boosted With Ritonavir (500 mg/200 mg qd, 250 mg/100 mg Bid and 500 mg/100 mg Bid) by Assessing the Steady-State Pharmacokinetics and Short-Term Efficacy and Safety in HIV-1 Positive Treatment naive Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2014

At a glance

  • Drugs Ritonavir (Primary) ; Tipranavir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 30 Jan 2009 Planned number of patients changed from 75 to 85 as reported by ClinicalTrials.gov.
    • 17 Jun 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
    • 11 May 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top